Search

Searching. Please wait…

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

 Authorship: Mateos M.V., Weisel K., Terpos E., Delimpasi S., Kastritis E., Zamagni E., Delforge M., Ocio E., Katodritou E., Gay F., Larocca A., Leleu X., Otero P.R., Schjesvold F., Cavo M., Dimopoulos M.A.,

 Fuente: Haematologica, 2024, 109(7), 2337-2340

 Publisher: Ferrata Storti Foundation

 Year of publication: 2024

 No. of pages: 4

 Publication type: Article

 DOI: 10.3324/haematol.2023.284694

 ISSN: 0390-6078,1592-8721